Turn Therapeutics (TTRX) officer buys 2,450 shares

Turn Therapeutics Inc. (TTRX) reported open-market stock purchases by its Interim Chief Financial Officer, Vice President of Finance & Chief Accounting Officer.

Rhea-AI Filing Summary

Turn Therapeutics Inc. (TTRX) reported open-market stock purchases by its Interim Chief Financial Officer, Vice President of Finance & Chief Accounting Officer. On 11/20/2025, the officer bought 1,450 shares of common stock at $2.61 per share, followed by another purchase of 1,000 shares at $3.29 per share on 11/21/2025. After these transactions, the officer beneficially owned 10,000 shares of Turn Therapeutics common stock, held directly.

Insider Trade Summary

Net Buyer: 2,450 shares

Net Buy 2 txns

Insider Chaudhary Zuraiz

Role See Remarks

Bought 2,450 shs ($7K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	1,000	$3.29	$3K
Purchase	Common Stock	1,450	$2.61	$4K

Holdings After Transaction: Common Stock — 10,000 shares (Direct)

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions were reported for Turn Therapeutics (TTRX)?

The Interim Chief Financial Officer, who is also Vice President of Finance & Chief Accounting Officer, reported two open-market purchases of Turn Therapeutics (TTRX) common stock on 11/20/2025 and 11/21/2025.

How many Turn Therapeutics (TTRX) shares did the officer buy and at what prices?

The officer purchased 1,450 shares of common stock at $2.61 per share on 11/20/2025 and 1,000 shares at $3.29 per share on 11/21/2025.

How many Turn Therapeutics (TTRX) shares does the reporting officer own after these trades?

Following the reported transactions, the officer beneficially owned 10,000 shares of Turn Therapeutics common stock in direct ownership.

What is the reporting person’s role at Turn Therapeutics (TTRX)?

The reporting person serves as Interim Chief Financial Officer, Vice President of Finance & Chief Accounting Officer of Turn Therapeutics Inc.

Is this Form 4 filed by one or multiple reporting persons for Turn Therapeutics (TTRX)?

This Form 4 is indicated as being filed by one reporting person for Turn Therapeutics Inc. (TTRX).

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 11/21/2025 - 05:43 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Chaudhary Zuraiz

(Last) (First) (Middle)

C/O TURN THERAPEUTICS INC.

250 N. WESTLAKE BLVD.

(Street)

WESTLAKE VILLAGE CA 91362

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Turn Therapeutics Inc. [ TTRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
11/20/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/20/2025		P		1,450	A	$2.61	9,000	D
Common Stock	11/21/2025		P		1,000	A	$3.29	10,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

Remarks:

Interim Chief Financial Officer, Vice President of Finance & Chief Accounting Officer.

	/s/ Zuraiz Chaudhary	11/21/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.